All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2021-06-25T09:48:50.000Z

The EC has extended approval for SC daratumumab + VCd for AL amyloidosis based on updated results from the phase III ANDROMEDA trial

Jun 25, 2021
Share:

Bookmark this article

On June 22, 2021, it was announced that the European Commission (EC) granted the extended approval of subcutaneous (SC) daratumumab in combination with bortezomib, cyclophosphamide, and dexamethasone (VCd) for the treatment of adults with newly diagnosed systemic light chain (AL) amyloidosis.1 This approval makes this regimen the first approved therapy for AL amyloidosis in Europe, although it has previously been approved in the U.S. by the U.S. Food and Drug Administration (FDA).   

This approval was based on results from the phase III ANDROMEDA trial (NCT03201965), which were updated at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Haematology Association (EHA)2021 Virtual Congress. The trial results demonstrated a significantly higher hematologic complete response rate with the addition of daratumumab to VCd compared with VCd alone (59% vs 19%; p < 0.0001). More patients achieved a very good partial response or better with daratumumab + VCd compared with VCd alone (79% vs 50%). The safety profile of daratumumab + VCd was also consistent with that previously observed for each agent alone.1,2

What challenges may occur when treating AL amyloidosis with Dara + VCd in a real-world setting?

During the EHA2021 Virtual Congress, Efstathios Kastritis, National and Kapodistrian University of Athens, Athens, GR, discussed these updated results and the challenges that may arise when treating AL amyloidosis with this regimen in a real-world setting. 

  1. Janssen. DARZALEX®▼ (daratumumab) subcutaneous (sc) formulation becomes the first approved treatment for newly diagnosed systemic light chain amyloidosis in Europe and gains an additional approval in pre-treated multiple myeloma. http://johnsonandjohnson.gcs-web.com/static-files/59e7757b-4327-40ce-89a5-5b81ae2b4152. Published Jun 22, 2021. Accessed Jun 23, 2021.
  2. Kastritis E, Sanchorawala V, Merlini G, et al. Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study. J Clin Oncol. 2021;39(no. 15_suppl):8003-8003. DOI: 1200/JCO.2021.39.15_suppl.8003

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox